ZITADEL
10.6.2022 11:50:09 CEST | Business Wire | Press release
ZITADEL, innovator of a transformative identity management platform, announces $2.5M in seed funding led by Nexus Venture Partners. The funding will help ZITADEL provide developers with a much-needed open-source alternative for their identity management needs and evolve its solution, scale sales growth, and nurture the open-source community. The current market landscape consists of established but closed-source players, including Auth0, Okta, Firebase, AWS Cognito, and others.
ZITADEL’s founding vision was based on the creation of a streamlined, cloud-native identity management platform to speed time-to-market for software projects. Focused on the simplicity of integration, ready-to-use self-service features, a customizable and secure login with first-class support for passwordless authentication, and an API-first strategy, ZITADEL’s unique turnkey platform offers developers unprecedented flexibility.
Developers often spend countless hours creating, configuring, and operating complex authentication and authorization systems. ZITADEL, which is built mainly in the Go programming language, solves these problems with easy-to-use integrations in multiple languages and frameworks. This flexibility enables developers to utilize prebuilt features provided by ZITADEL to dramatically improve their productivity. In addition, ZITADEL’s capabilities address existing open-source projects which were not built for a cloud-native and serverless environment.
The ZITADEL team is working towards further enriching the solution’s enterprise-readiness. New capabilities include multi-tenancy, unlimited audit trails, improved ability to self-host, and support for serverless deployments, plus the potential to extend ZITADEL’s breadth with custom code created in WebAssembly. Combined with its cloud-native architecture, ZITADEL’s self-hosting capabilities allow privacy-focused customers to own and control their data by running a dedicated version. ZITADEL’s flexible model, with its span of smart efficiency enhancements, is already the go-to solution for numerous marquee enterprise customers.
The generous free tier of ZITADEL’s cloud-hosted offering allows anybody to create a ZITADEL instance in under five minutes—without a credit card. In its ongoing commitment to deliver GDPR support to its customers, ZITADEL Cloud also provides the capability to define the country or geopolitical region in which to store their data.
“Amidst today's complex software projects, ZITADEL provides a turnkey solution that allows developers to get started easily with a secure login, user management, multi-factor authentication, social logins, authorization management, and great APIs. With ZITADEL, we provide an important component to improve the overall security of a project while reducing your time-to-market,” said ZITADEL Co-Founder and CEO, Florian Forster.
“We’re delighted to break new ground partnering with Florian and the ZITADEL team, our first-ever investment in a Swiss company. We believe the future of digital identities is passwordless. ZITADEL takes a developer-first, open-source approach to solving identity management. Its simple and easy-to-integrate building blocks help developers build secure authentication into their applications without requiring deep in-house expertise and resource commitment.” said Abhishek Sharma, Managing Director at Nexus Venture Partners. “ZITADEL is the latest addition to the Nexus family of over a dozen marquee commercial open-source companies,” added Sharma.
About ZITADEL
ZITADEL is the modern open* alternative for Auth0, Firebase Auth, and AWS Cognito, as well as Keycloak, built for the container and serverless era. It provides customers a wide range of out-of-the-box features, including secure login, self-service, OpenID Connect, OAuth2.x, SAML2, branding, Passwordless with FIDO2, OTP, U2F, and an unlimited audit trail to improve the life of developers and developers. With its legal incorporation in Switzerland, ZITADEL is in the unique position of providing its cloud services even to customers with the strictest GDPR requirements. For more information visit https://zitadel.com , follow @zitadel on Twitter, or star the repository https://github.com/zitadel/zitadel on GitHub
About Nexus Venture Partners
Nexus Venture Partners is an early-stage venture capital firm partnering with extraordinary entrepreneurs to help build product-first software companies. With $2 billion under management, Nexus operates as one team across the U.S. and India. The Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Rapido, Sibros, TileDB, Turtlemint, Unacademy, WhitehatJr, and Zepto. For more information, visit www.nexusvp.com or follow @nexusvp on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom